Practical Considerations to Manage Residual ASCVD Risk

Practical Considerations to Manage Residual ASCVD Risk

Practical Considerations to Manage Residual ASCVD Risk

Dr. Sergio Fazio shares the latest evolving guidelines on risk stratification and management of ASCVD risk reduction beyond statin therapy.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The therapeutic landscape for ASCVD is evolving rapidly. Stay ahead of the clinical curve with this video presentation with slides, featuring renowned cardiovascular expert Dr. Sergio Fazio, Professor of Medicine and Director of the Center for Preventive Cardiology at Oregon Health & Science University. Dr. Fazio highlights a recent ACP symposium and shares practical considerations on the latest guidelines for risk stratification and new guideline-recommended approaches to the management of atherosclerotic cardiovascular disease (ASCVD) risk reduction beyond statin therapy.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Sergio Fazio, MD, PhD
    The William and Sonja Connor
    Chair of Preventive Cardiology
    Professor of Medicine and Physiology & Pharmacology
    Director, Center for Preventive Cardiology
    Knight Cardiovascular Institute
    Oregon Health & Science University
    Portland, OR 

    Consulting Fees: Amarin Pharma Inc., Amgen, AstraZeneca,
    Kowa Pharmaceuticals America, Inc., Novo Nordisk

    Reviewers/Content Planners/Authors:

    • Ben Caref, PhD, has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Have greater clarity on risk assessment and management based on the 2018 ACC/AHA Multisociety Guideline on the Management of Blood Cholesterol
    • Apply evidence-based guidelines, recent trial evidence, and utility of ASCVD therapies in practice
  • Target Audience

    This activity is designed to meet the educational needs of internists, primary care physicians, hospitalists, and allied healthcare professionals, including pharmacists, nurse practitioners, physician assistants, dietitians, and nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free